205 related articles for article (PubMed ID: 31425654)
1. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
[TBL] [Abstract][Full Text] [Related]
2. Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations.
Mihalovits LM; Ferenczy GG; Keserű GM
J Chem Inf Model; 2020 Dec; 60(12):6579-6594. PubMed ID: 33295760
[TBL] [Abstract][Full Text] [Related]
3. Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors?
Chatterjee P; Botello-Smith WM; Zhang H; Qian L; Alsamarah A; Kent D; Lacroix JJ; Baudry M; Luo Y
J Am Chem Soc; 2017 Dec; 139(49):17945-17952. PubMed ID: 29124934
[TBL] [Abstract][Full Text] [Related]
4. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
Kumalo HM; Bhakat S; Soliman ME
Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
[TBL] [Abstract][Full Text] [Related]
5. Accurate and Reliable Prediction of the Binding Affinities of Macrocycles to Their Protein Targets.
Yu HS; Deng Y; Wu Y; Sindhikara D; Rask AR; Kimura T; Abel R; Wang L
J Chem Theory Comput; 2017 Dec; 13(12):6290-6300. PubMed ID: 29120625
[TBL] [Abstract][Full Text] [Related]
6. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring.
Zhu K; Borrelli KW; Greenwood JR; Day T; Abel R; Farid RS; Harder E
J Chem Inf Model; 2014 Jul; 54(7):1932-40. PubMed ID: 24916536
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations.
Mons E; Roet S; Kim RQ; Mulder MPC
Curr Protoc; 2022 Jun; 2(6):e419. PubMed ID: 35671150
[TBL] [Abstract][Full Text] [Related]
8. Predicting the Relative Binding Affinity for Reversible Covalent Inhibitors by Free Energy Perturbation Calculations.
Bonatto V; Shamim A; Rocho FDR; Leitão A; Luque FJ; Lameira J; Montanari CA
J Chem Inf Model; 2021 Sep; 61(9):4733-4744. PubMed ID: 34460252
[TBL] [Abstract][Full Text] [Related]
9. Advances in covalent kinase inhibitors.
Abdeldayem A; Raouf YS; Constantinescu SN; Moriggl R; Gunning PT
Chem Soc Rev; 2020 May; 49(9):2617-2687. PubMed ID: 32227030
[TBL] [Abstract][Full Text] [Related]
10. Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action.
Patel D; Huma ZE; Duncan D
ACS Chem Biol; 2024 Apr; 19(4):824-838. PubMed ID: 38567529
[TBL] [Abstract][Full Text] [Related]
11. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
Aljoundi A; Bjij I; El Rashedy A; Soliman MES
Protein J; 2020 Apr; 39(2):97-105. PubMed ID: 32072438
[TBL] [Abstract][Full Text] [Related]
12. Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations.
Cournia Z; Allen B; Sherman W
J Chem Inf Model; 2017 Dec; 57(12):2911-2937. PubMed ID: 29243483
[TBL] [Abstract][Full Text] [Related]
13. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.
Johnson DS; Weerapana E; Cravatt BF
Future Med Chem; 2010 Jun; 2(6):949-64. PubMed ID: 20640225
[TBL] [Abstract][Full Text] [Related]
14. The expanding repertoire of covalent warheads for drug discovery.
Mehta NV; Degani MS
Drug Discov Today; 2023 Dec; 28(12):103799. PubMed ID: 37839776
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Covalent Ligands via Noncovalent Docking by Dissecting Covalent Docking Based on a "Steric-Clashes Alleviating Receptor (SCAR)" Strategy.
Ai Y; Yu L; Tan X; Chai X; Liu S
J Chem Inf Model; 2016 Aug; 56(8):1563-75. PubMed ID: 27411028
[TBL] [Abstract][Full Text] [Related]
16. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
Hafner J
J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
[TBL] [Abstract][Full Text] [Related]
17. A Perspective on the Kinetics of Covalent and Irreversible Inhibition.
Strelow JM
SLAS Discov; 2017 Jan; 22(1):3-20. PubMed ID: 27703080
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the noncovalent binding mode of covalent proteasome inhibitors around the transition state by combined use of cyclopropylic strain-based conformational restriction and computational modeling.
Kawamura S; Unno Y; Tanaka M; Sasaki T; Yamano A; Hirokawa T; Kameda T; Asai A; Arisawa M; Shuto S
J Med Chem; 2013 Jul; 56(14):5829-42. PubMed ID: 23837692
[TBL] [Abstract][Full Text] [Related]
19. Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation.
Yu W; Weber DJ; MacKerell AD
J Chem Theory Comput; 2023 May; 19(10):3007-3021. PubMed ID: 37115781
[TBL] [Abstract][Full Text] [Related]
20. Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking.
Zhang H; Jiang W; Chatterjee P; Luo Y
J Chem Inf Model; 2019 May; 59(5):2093-2102. PubMed ID: 30763080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
